Repligen Corporation, founded in 1981 and headquartered in Waltham, Massachusetts, United States, provides advanced bioprocessing technologies to the global biopharmaceutical industry. The company drives revenue by supplying proprietary reagents, chromatography resins, and single‐use systems to major pharmaceutical firms. Under the leadership of CEO Robert E. Dutton, Repligen has secured an estimated 15-20% market share in its niche through innovative process solutions. It is focused on strategic expansion and R&D investments to fuel double-digit growth in the near term.